Exact Sciences Corporation struggles with profitability due to high expenses. See why EXAS stock faces challenges despite the ...

Exact Sciences has enlisted Lil Jon, the poop emoji and a singing toilet for its latest Cologuard marketing push, remixing ...

Early 2000s kids, listen up! Lil Jon is re-releasing a beloved beat to get you ahead of the game: "You can survive it if it's ...

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy ...

Included was a final decision related to CMS pricing for Exact Sciences Corp’s (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes ...

Lil Jon is partnering with Exact Sciences, the maker of Cologuard®, to encourage the 60M people in the U.S. not up to date with screening for colon cancer to get screened. (Photo: Exact Sciences ...

Lil Jon is channeling his smash hit "Get Low" to motivate those 45 and up to get low with a colon cancer screening.

Furthermore, this favorable pricing development is expected to significantly impact Exact Sciences’ financial performance. With the anticipated launch of Cologuard Plus in the second quarter of ...

primarily driven by Exact Sciences’ recent achievement in securing a price increase for its Cologuard Plus test. The company successfully obtained a price of approximately $592 per test through ...

On Tuesday, Wolfe Research maintained a positive outlook on Exact Sciences (NASDAQ:EXAS), reiterating an Outperform rating and a $70.00 price target. The firm's analysis indicates that the launch of ...

In June, at the Clinical Lab Fee Schedule (CLFS) Annual Meeting, Exact Sciences proposed a 1.25 times price increase for Cologuard Plus. The independent panel's vote in July leaned in favor of ...